Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$KNDI Now $2,500 rebate for its Electric Vehicles in Texas USA.
Is Iqstel ( $IQST) Going to Hit $1 Mark in January https://ih.advfn.com/p.php?pid=nmona&article=84105048
$NGTF - News on high profile new partnership with famous Papa John's chain:
Nightfood and Papa John's Satisfy Late Night Cravings with Double Cheeseburger Papadias and Pickles for Two Ice Cream
TARRYTOWN, NY, Nov. 23, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nightfood, Inc. (OTCQB: NGTF), the company pioneering the category of nighttime snacks for better sleep, today announced Nightfood’s Pickles For Two ice cream is being featured along with a Double Cheeseburger Papadia from Papa John’s in a gift pack as part of a promotional partnership.
“We’re honored to have been invited by Papa John’s to participate in this national promotion satisfying late-night cravings,” commented Nightfood CEO Sean Folkson. “We’re excited to be able to introduce our Pickles For Two, and the entire Nightfood brand, to so many new consumers.”
Nightfood ice cream was developed by leading sleep experts for nighttime snacking with ingredients for relaxation and better sleep. A better choice for men, women, and children of all ages, Nightfood pints feature more protein, fiber, calcium, magnesium, and zinc, and less sugar, less fat, and fewer calories than regular ice cream.
The company recently launched the Pickles For Two flavor to satisfy the two most popular pregnancy cravings: pickles and ice cream. Nightfood was named this year as the official ice cream of the American Pregnancy Association. And now, the two companies are bringing consumers the opportunity to satisfy all of their late-night pickle cravings with Pickles for Two ice cream and the Papa John’s Double Cheeseburger Papadia, which also features crunchy pickles.
In addition to Pickles For Two, Nightfood ice cream comes in many traditional flavors, including Cold Brew Decaf, Cookies n’ Dreams, Midnight Chocolate, Full Moon Vanilla, Milk & Cookie Dough, Bed and Breakfast, Cherry Eclipse, and After Dinner Mint Chip.
Papa John’s Double Cheeseburger Papadia is a fan-favorite, available for a limited time only. It features a quarter pound of seasoned beef with crispy pickles and melty cheese baked to a toasty perfection. The Double Cheeseburger Papadia is served with Papa John’s signature burger dipping sauce for a maximum flavor experience.
As part of the promotion, influencers and other consumers were selected to receive a custom cooler, pints of Nightfood’s Pickles For Two, and of course, a Papa John’s Double Cheeseburger Papadia, delivered by their local Papa John’s location. Nightfood ice cream is not available for consumer purchase from Papa John’s as part of this promotional partnership.
About Nightfood Holdings:
Nightfood Holdings, Inc. (OTC: NGTF), owns Nightfood, Inc. and MJ Munchies, Inc.
Nightfood has expanded distribution for its ice cream into major divisions of the largest supermarket chains in the United States: Kroger (Harris Teeter), Albertsons Companies (Jewel-Osco and Shaw’s and Star Markets), and H-E-B (Central Market) as well as Lowe’s Foods, Rouses Markets, and other independent retailers.
Nightfood won the 2019 Product of the Year award in the ice cream category in a Kantar survey of over 40,000 consumers. Nightfood was also named Best New Ice Cream in the 2019 World Dairy Innovation Awards.
Nightfood has been endorsed as the Official Ice Cream of the American Pregnancy Association and is the recommended ice cream for pregnant women. There are approximately 3,000,000 pregnant women in the United States at any given time, and ice cream is the single most-widely reported pregnancy craving. With more calcium, magnesium, zinc, fiber, and protein, less sugar and a lower glycemic profile than regular ice cream, Nightfood has been identified as a better choice for expectant mothers.
Nightfood is not just for pregnant women. Over 80% of Americans snack regularly at night, resulting in an estimated 700M+ nighttime snack occasions weekly, and an annual spend on night snacks of over $50 billion dollars, the majority of it on options that are understood to be both unhealthy, and disruptive to sleep quality.
Nightfood was formulated by sleep and nutrition experts with ingredients that research suggests can support nighttime relaxation and better sleep quality. Scientific research indicates unhealthy nighttime cravings are driven by human biology. Willpower is also weakest at night, and stress is another contributing factor. A majority of night snackers report feeling both guilty and out-of-control when it comes to their nighttime snacking.
Because unhealthy night snacking is believed to be biologically driven, and not a trend or a fad, management believes the category of nighttime-specific nutrition, which Nightfood is pioneering, can be a billion-dollar category.
MJ Munchies, Inc. was formed in 2018 as a new, wholly owned subsidiary of Nightfood Holdings, Inc. to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. The Company is seeking licensing opportunities to market such products under the brand name “Half-Baked”, for which they’ve successfully secured trademark rights.
Questions can be directed to investors@Nightfood.com
Management also encourages Nightfood shareholders to connect with the Company via these methods:
E-mail: By signing up at ir.nightfood.com, investors can receive updates of filings and news releases in their inbox.
Telegram: There is now a live, interactive Telegram group which interested parties can join to reach team members and discuss Nightfood. Ask questions, learn more about the company and discuss future prospects. Join the Telegram Group Here: https://t.me/NightfoodHoldings
YouTube: The company has established a new YouTube series which will feature weekly videos with team members, insights into latest industry developments, and provide a behind the scenes look at the latest company developments. Click here to subscribe to Nightfood’s YouTube channel.
About Papa John’s
Papa John’s International, Inc. opened its doors in 1984 with one goal in mind: BETTER INGREDIENTS. BETTER PIZZA.® Papa John’s believes that using high quality ingredients leads to superior quality pizzas. Its original dough is made of only six ingredients and is fresh, never frozen. Papa John’s tops its pizzas with real cheese made from mozzarella, pizza sauce made with vine-ripened tomatoes that go from vine to can in the same day and meat free of fillers. It was the first national pizza delivery chain to announce the removal of artificial flavors and synthetic colors from its entire food menu. Papa John’s is headquartered in Louisville, Ky. and is the world’s third largest pizza delivery company with more than 5,360 restaurants in 48 countries and territories as of September 27, 2020. For more information about the Company or to order pizza online, visit www.PapaJohns.com or download the Papa John’s mobile app for iOS or Android.
Forward-Looking Statements:
This current press release contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, any products sold or cash flow from operations.
Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with distribution and difficulties associated with obtaining financing on acceptable terms. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Media Contact:
Tim Sullivan
media@Nightfood.com
732-816-0239
Investor Contact:
Stuart Smith
investors@Nightfood.com
888-888-6444, x3
Attachment
NIghtFood, Inc.
Weeks's Breakout Stock: ENDV!
Target, somewhere around.14c! that is almost 5 fold increase from the current price!..
This is a notorious bad performer, repeat offender bad stock on OTC!.. but, when you look at the technical s, it is ready for a Run!..today's is not the day but this week, that means tomorrow or next week a Breakout is imminent!..
Endonovo Therapeutics Inc (ENDV)
0.0300 -0.0019 (-5.96%) 15:25 ET [OTC US]
Quote Overview for Fri, Jan 8th, 2021
Today's Breakout Stock!... this will be a Fantastic breakout stock:
Immediate Target price: $2.0 and 3.25, and beyond!
Reflect Scientific Inc (RSCF)
0.5000 +0.1030 (+25.94%) 15:19 ET [OTC US]
Quote Overview for Fri, Jan 8th, 2021
Holy Hanna cabana
Thanks penny :)
Thanks DD75, it is on a bull mode!, more to go, I will follow up!
Penny check RSCF volume coming in
$CURR News: CURE Pharmaceutical to Present at H.C. Wainwright BioConnect 2021 Virtual Conference
Press Release | 01/07/2021
CURE Pharmaceutical Holding Corp (“CURE” or the “Company”) (OTC: CURR), a technology-focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced today that the Company’s Chief Executive Officer Rob Davidson will be presenting at the H.C. Wainwright BioConnect 2021 Virtual Conference being held January 11-14. The presentation can be viewed beginning at 6:00 a.m. EST on January 11, 2021, and can be accessed here through registration and will be available online until January 14.
During the presentation, Davidson will discuss how CURE’s recent acquisition of Sera Labs greatly expands the Company’s positioning as a global health and wellness leader through added distribution channels and revenue streams. Furthermore, he will give additional insight into the importance of CURE’s recently approved Investigational New Drug (IND) application for its product CUREfilm Blue™ intended to treat ertictile dysfunction (ED) which utilizes the Company’s proprietary CUREfilm™ drug delivery technology. Finally, he will discuss the Company’s fiscal strategy for the upcoming year and new opportunities these milestones have created for the Company.
"The last six months have been pivotal for CURE. To name just a few achievements, we repositioned our fiscal strategy and greatly expanded our operations with the acquisition of Sera Labs, welcomed Nicole Kidman as Sera Labs’ strategic business partner and global brand ambassador and just received approval on our IND application for CUREfilm Blue™," Davidson said. “As we head into 2021, I look forward to sharing additional insight into these milestones with conference attendees and share how I believe CURE is well positioned to capitalize on our mission of delivering the promise of healthier lives to patients and consumers all over the world.”
About CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.
As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® and cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.
Forward Looking Statement
Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect CURE’s judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005306/en/
NEXT MAJOR OR MASSIVE BREAKOUTS"
[OPK, IDEX, FLES, PFE, WLDF, PAOG, PURA, HBRM & VIBI
Opko Health INc- OPK
1.
Opko Health Inc (OPK)
4.48 +0.08 (+1.82%) 01/07/21 [NASDAQ]
4.47 x 67 4.50 x 51
Post-market 4.50 +0.02 (+0.45%) 17:56 ET
Quote Overview for Thu, Jan 7th, 2021
2.
Ideanomics: IDEX
Ideanomics Inc (IDEX)
2.98 +0.79 (+36.07%) 01/07/21 [NASDAQ]
2.96 x 13 2.97 x 422
Post-market 2.97 -0.01 (-0.34%) 18:15 ET
Quote Overview for Thu, Jan 7th, 2021
For 4 Less Group:
The 4 Less Group Inc (FLES)
1.9000 +0.2200 (+13.10%) 01/07/21 [OTC US]
Quote Overview for Thu, Jan 7th, 2021
Pfizer Inc (PFE)
37.06 +0.19 (+0.52%) 01/07/21 [NYSE]
37.01 x 4 37.03 x 1
Post-market 37.03 -0.03 (-0.08%) 18:13 ET
Quote Overview for Thu, Jan 7th, 2021
SMME is a good pick Profitscout!!....keep visiting the board and post your good picks..!!
$LRSV $CBDL $CBDD $CEBHF Four Cannabis Stocks To Consider in 2021"
Click Here:
https://cannabishempwire.com/latest-news/f/4-cannabis-stocks-to-consider-in-2021-cwbhf-lrsvcbdd-cbdl
CBD Life Sciences Inc. (CBDL) Updates Its Shareholders for 2021. https://finance.yahoo.com/news/cbd-life-sciences-inc-cbdl-120000483.html
WOW!! Analysts think Westwater Resources, Inc. (NASDAQ: $WWR) could rise 2942.6% from current levels https://stocksregister.com/2021/01/04/analysts-think-westwater-resources-inc-nasdaqwwr-could-rise-2942-6-from-current-levels/ via @Stocks Register
$CURR is well financed to continue developing and marketing the company's important developments for enhanced drug delivery and CBD wellness products marketing.
CURE Pharmaceutical Closes $10 Million Financing
Press Release | 11/02/2020
CURE Pharmaceutical Holdings (OTC: CURR), a developer and manufacturer of innovative delivery formulations for drugs, supplements and wellness products, today announced that it has received the first tranche of $4 million of a committed financing of $10 million, after original issue discounts, through the issuance of convertible notes (the “Notes”). Axiom Capital Management, Inc. acted as the sole placement agent in the transaction.
CURE may repay the obligations of the Notes in cash only, or the Notes may be converted upon election of the investor at a fixed price of $1.32 per share subject to certain adjustments.
“This financing will enable us to achieve a number of key company goals and sets the stage for making 2021 a breakout year for CURE,” stated Rob Davidson, CEO of CURE. “We have already set in motion the steps needed to drive progress in two key areas: driving strong sales growth of newly acquired Sera Labs, and advancing our clinical pharmaceutical pipeline, particularly CURE’s lead clinical development program for CUREfilm Blue™ (our trademarked name for sildenafil, or generic Viagra, to treat erectile dysfunction on our novel oral thin film technology).”
The securities sold in the financing transaction have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other applicable jurisdiction’s securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. CURE has agreed to file a registration statement with the United States Securities and Exchange Commission registering the resale of the shares of common stock issuable upon conversion of the Notes.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
For additional information on this financing transaction, see the associated Form 8-K which will be available in CURE’s public filings.
About CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate-release and controlled-release drug delivery technologies designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients. CURE’s delivery technologies include CUREfilm®, an advanced oral thin film; and CUREdrops™, an emulsion technology that can be incorporated into different dosage forms (film, tincture, beverages, etc.), among others. CURE’s proprietary clinical pipeline includes CUREfilm®Blue (sildenafil to treat erectile dysfunction), and CUREfilm®Canna (THC and CBD). As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® and cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.
Sera Labs
Wholly owned subsidiary, Sera Labs has redefined the beauty, health & wellness, and pet care sectors by using science-backed, proprietary formulations, exceptional ingredients, (including organic CBD), and combined them with innovative sales & marketing strategies. Sera Labs’ products are sold in major national drug store, grocery, and mass retail chains under the brand names Sera Labs™, SeraRelief™ and SeraTopical™. Sera Labs also sells its products via private labeled for major retailers and multi-level marketers. Consumers can also purchase Sera Lab’s products directly from its web site, which offers a compelling, opt-in subscription service for greater savings and broad accessibility to consumers worldwide. For more information visit: www.Seralabshealth.com and follow @theseralabs.
Forward-Looking Statements
Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect CURE’s judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201102005090/en/
$760,000.00 in Sales Expected for Gevo, Inc. (NASDAQ: $GEVO) This Quarter https://www.marketbeat.com/instant-alerts/nasdaq-gevo-consensus-analyst-rating-2021-01/
$KNDI The Agricultural Bank of China Hangzhou Branch will provide Kandi with an RMB 500M (~$76.5M) line of credit to support the first phase of the "300,000 government-accredited program. Additional credit will be provided based on the business progress. https://seekingalpha.com/news/3647687-kandi-technologiesplus-15-after-announcing-agreement-hangzhou-branch-of-agricultural-bank-of
$Elys Game Technology Becomes First Dual Listing Technology Company From NASDAQ to NEO Exchange | Business Wire https://www.businesswire.com/news/home/20201230005128/en/Elys-Game-Technology-Becomes-First-Dual-Listing-Technology-Company-From-NASDAQ-to-NEO-Exchange#.X-x69J0pjoE.twitter
Gytuste on GEVO
Always good to review useful information:
GEVO – KEY INVESTOR “TAKE-AWAYS”
• Proven technologies
– Products proven to work
– Production processes work
– Intellectual Property (IP) valued +$400 million*
• Huge end markets and we can solve problems around GHG’s for liquid fuels leveraging existing transportation fuel infrastructure and cars, trucks, planes
• Long-term, take or pay contracts in place, more developing. – Strong, Global Players
• Focus on growing large scale production plants, and off-balance sheet financing. Economics are attractive (+20% IRR)** – Citigroup Project, multiple term sheets for equity investments in hand
– 45MGPY plant planned for Lake Preston, SD
– Other sites in development
• Have the money for development on the balance sheet
• Gevo has multiple routes to make money (License fees, operating fees, project management fees, equity ownership, etc)
Analysts Say You Should Buy Your Position in Elys Game Technology, Corp. (NASDAQ: $ELYS) https://stocksregister.com/2020/12/28/analysts-say-you-should-buy-your-position-in-elys-game-technology-corp-nasdaqelys/ via @Stocks Register
They say WWR could go to $150.00!!! read on:
An in-depth look at the Westwater Resources, Inc. ( $WWR) stock https://marketingsentinel.com/2020/12/28/an-in-depth-look-at-the-westwater-resources-inc-wwr-stock/ via @Marketing Sentinel
Gevo, Inc. (NASDAQ: $GEVO) 17.97% gain reignites investor interest in company’s stock https://stocksregister.com/2020/12/28/gevo-inc-nasdaqgevo-17-97-gain-reignites-investor-interest-in-companys-stock/ via @Stocks Register
Boiling and ready to burst as Ideanomics Inc. ( $IDEX) last month performance was 70.00% https://investchronicle.com/2020/12/22/boiling-and-ready-to-burst-as-ideanomics-inc-idex-last-month-performance-was-70-00/ via @Invest Chronicle
Buying here $KNDI great price entry
Thanks SOT but compare the SS and see
why I went to ELYS.
Don't stop posting or take it the wrong way....Don't mean anything personal.
$ALYI ALYI Plans To Take Pre-Orders For Its Retro ReVolt Electric Motorcycle Starting In December
https://finance.yahoo.com/news/alyi-announces-plans-pre-orders-142500662.html
$ALYI Alternet Systems, Inc., through its subsidiaries, focuses on providing digital payments and data analytics, micro segmentation, and marketing intelligence services for the mass consumer goods, payments, financial services, and telecommunications sectors. It offers financial services software, including biometric authentication, multichannel payment solutions, electronic point of sale modernization, payment processing, and data analytics tools, as well as NFC point of sale solutions for the mobile financial industry. The company is also involved in the modernization of the electronics point of sale legacy infrastructure expanding the useful life of the electronic point of sale; and including new payment functions in the terminals, such as bill payment, electronic top-up, and native payments with digital currency at the point of sale. In addition, it provides data analytics tools and services for the telecommunications and financial services industries. Further, the company produces and sells electric motorcycles. The company holds a partnership with iQSTEL, Inc. to codevelop two-way device communication solutions specific to the EV operating environment. Alternet Systems, Inc. is headquartered in Miami, Florida. https://finance.yahoo.com/quote/ALYI?p=ALYI&.tsrc=fin-srch
$MJNA First to Introduce Legal Medical Cannabis Products to Brazil
In April of 2014, Real Scientific Hemp Oil™ (RSHO™) became the first medical cannabis product to be approved for import and use in Brazil when the country allowed access for a little girl with epilepsy.
https://www.medicalmarijuanainc.com/company-of-firsts/the-first-to-create-medical-cannabis-products-to-brazil/
Breakouts Bio-Stock today: IBIO
================================
This small cap to mid cap biotech/biopharma company's stock had gone through perilous loss of stock price for the last several months (the Peak was 7/22/2020), and it bottomed yesterday or this week to say, not much downside from here!.
Ibio Inc (IBIO)
1.1400 unch (unch) 12/18/20 [NYSE Arca]
1.1500 x 79 1.1600 x 106
Pre-market 1.1600 +0.0200 (+1.75%) 09:11 ET
Quote Overview for Fri, Dec 18th, 2020
Immediate, short term target prices: $1.72 and 2.42, more upside is possible with reports and progress in trials..!!
$ELYS OVER $3.00!!! With VOLUME it COULD go to $5.00 QUICKLY!!!
jmo
$ALYI Electric Vehicles
SpotOnT, what is the connection?, are these two co's related in any way or you simply highlighting KNDI for the recent contract deals?
Kandi Technologies $KNDI receives second certification from California Air Resources Board
Next Big Breakout Penny Stock: LVGI 1000-5000% is a possibility! Why?
It is a 11M float stock, so small the float is, such stocks skyrocket when you blink!?. But, the O/S and A/S is tiny too for a company of this size and calber, the share structure is fantastic! multiple revenue generators already blowing up estimates..
And, most importantly, it is like a holding co with several lines of business, the Cannabis/Hemp connection alone is just enough to be a outstanding performer, take a look at what the CEO said recently about their blow out Revenues!
Don't forget $ELYS upper $2.00s-Low $3.00s...
The DD is GREAT on this one. Online betting HUGE in Italy, making
a run at moving to America!!
Skys the limit!! imo
$SMME - The company's advanced biometric scanning tech to defeat fraudulent charges on credit and debit cards is greatly needed across the board but the company has now gone the extra mile to offer contactless solutions as well. This latest effort by the SMME team can help protect users not only from fraudulent usage but also from the ongoing threat of the pandemic issue.
SmartMetric Biometric Contactless Credit and Debit Cards Are the Perfect Solution for No Keypad Touch Card Transactions
Press Release | 08/04/2020
SmartMetric, Inc. (OTCQB: SMME) says that in the brave new world post Covid-19 it has become clear that consumers are wanting to lessen their exposure to public touch points when navigating the out-of-home world.
Leaving the confines and safety of a person's home takes the consumer into a shopping environment where they can expose themselves to virus infection. One of the common points of risk exposure is at the checkout counter. A credit and debit card key pad that is not cleaned after every transaction has become a serious touch point that can transfer viruses from one customer to another.
Mitigating the risk of the payment card touch keypad when entering a PIN to complete a transaction is something that is now a public health issue. Obviously, the best solution is to have no keypad entry needed when making a transaction.
While most credit and debit cards are now what is called contactless, the contactless transaction is dollar amount limited. Because a contactless card is inherently insecure, for transactions generally over $20.00 you are still required to put in your PIN at the checkout. Low transaction limits along with the need to touch the checkout keypad don’t make contactless card transactions as they are now designed an answer to true non-touch card usage at the checkout.
Contactless card transactions to buy a cup of coffee work fine. It is when you have just bought $150.00 of groceries that you have issues. Presently for such a purchase there is no getting around the requirement of using a keypad that usually between 10 and 20 people touch between store cleaning wipedowns.
The SmartMetric biometric credit and debit card is the perfect solution for true non-contact card use. With its built-in fingerprint sensor on the card that scans the card holders’ fingerprint when they touch the surface of their card. Their card scans their fingerprint, matches it with their fingerprint stored inside the card and in less than half a second authenticates the card user and turns on the card to send and receive a contactless signal to the reader.
Using a card user's own biometrics stored inside their own credit or debit card is far more secure in validating the authentication of the card user than the weaker security of a four digit PIN. It is now not only more secure than a PIN but allows the contactless credit or debit card to be used without the very low point of sale dollar transaction imposed on current contactless cards. All without the need to touch a suspect unclean card touch pad.
“We see consumer behavior being forever changed post Covid-19 with consumers still wanting to reach for their card to make a payment, but not wanting to touch PIN pads and readers at the checkout,” said today SmartMetric’s President and CEO, Chaya Hendrick.
SmartMetric is ready to move aggressively forward in making available its new card to credit and debit card issuing Banks around the world, in association with the its global banking partners.
SmartMetric is a USA based company with sales and marketing partnerships in Latin America, Europe the United States. Engineering of the biometric card electronics is done in-house and is the owned intellectual property of the company.
To view the SmartMetric Biometric Card please follow this link - Video of the SmartMetric Biometric Card To view the company website: www.smartmetric.com
Safe Harbor Statement: Forward-Looking Statements in this press release, which are not historical facts, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Also such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "will," "would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by us and our management, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, among others, if we are unable to access the capital necessary to fund current operations or implement our plans for growth; changes in the competitive environment in our industry and the markets where we operate; our ability to access the capital markets; and other risks discussed in the Company's filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K, which filings are available from the SEC. We caution you not to place undue reliance on any forward-looking statements, which are made as of the date of this press release. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. Investors and security holders are urged to carefully review and consider each of SmartMetric Inc. public filings with the SEC, including but not limited to, if applicable, Annual Reports on Form 10-K, proxy statements, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200804005956/en/
Ideanomics Inc. ( $IDEX) market price of $2.12 offers the impression of an exciting value play
https://investchronicle.com/2020/12/07/ideanomics-inc-idex-market-price-of-2-12-offers-the-impression-of-an-exciting-value-play/ via @Invest Chronicle
IDEX 96% BUY Rating:
https://www.barchart.com/stocks/quotes/IDEX/opinion
Kaly to Begin breakout tomorrow, it will be moving up towards .003-.007! or further high into .009-.0012!!!
Massive Breakouts of a Love & Hate Penny stock of the year:
These are some of the most hated Penny stocks traded in the OTC platform, and also loved by some or to some extent!...
Paog, Pura, Kaly, USMJ & Nouv, along with Alkami and ALYI!!!
As of this Post, as of this very moment you read, you are going to see a breakout out happening, but that is just the beginning, as these stocks and price performance was so bad over the months and years in the past mainly due to "dividend" claims, "too many" press release of claims of promises, and "too many unsubstantiated" acquisitions and mergers etc!.... almost to the point of hating this company stock and the people behind!... sure it is a bad management, and propaganda type of communications!..
but, in the midst of all these, there are some good news and good things happening, they have products, they have business lines and selling, bringing in money, which is the most important aspect of a co or stock!..
Though the financials are not clear as to profitability or assets, it is a speculative Penny play, and the stocks (all of them) will move up, significantly and stunning price movement is in the making!..
do your home work, check out what is going on with these companies on your own!..
Followers
|
31
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
742
|
Created
|
01/04/19
|
Type
|
Free
|
Moderator Pennyes | |||
Assistants i_am_andrew84 |
Share this Board with other investors and share also my other boards and invite others to join and discuss Penny Stocks: sign up to receive updates, post your stock interests."MOST OF THE "SO CALLED BLUE CHIPS" OR "$100 DOLLAR STOCKS, OR '$1000 DOLLAR STOCS" ARE SYSTEMATICALLY HYPED UP, PROMOTED "Noisy" STOCKS. WHEN THEY CRASH, EVERYTHING WILL BE LOST. MOST OF THE STOCKS IN GENERAL ONCE A PENNY STOCKS, MOST OF THEM BEGAN AS PENNY STOCKS, ONCE THE STOCK MOVES ABOVE FEW DOLLARS, THEY UPLIST AND MOVE ON, THATS FINE, BUT BADMOUTHING OR GO AGAINST PENNY STOCKS?...TALK NEGATIVELY ABOUT PENNY STOCKS, THATS DECEPTION AT ITS WORST!?. Most of the penny stocks traded for pennies before transforming into bigger or much richer company?. Penny stocks considered to be small cap or ultra small cap with little amount of money, most of the time a "Million or few Million" Market cap, however, it provided a foundation to build. It is important to protect and promote Penny stock sector, instead what big companies, corporations, business news media and govt agents do is to speak negatively about it, THEY ALL GIVE A DAMN ABOUT PENNY STOCKS OR THE SECTOR AND SPEAK "ASININE"ABOUT IT].
Penny Stocks and Penny Stock Sectors are Heavily and Systematically "Discredited, badmouthed and Negatively Portrayed by "Maistream Fake Media (TVs and News papers), Vested Interests, Big Corporations, Business Media, and so on. There is "No Truth" to it, Absolutely zero truth to their Propoganda, its has been going on for Decades, In Contrast, Penny Stocks are a Great Opportunity Investment area, because it is cheap, low priced and utterly cheap and mostly traded by small time investors, newbies and not so well trained investing communites, its kind of a "Deliberatly" kept away due to fear of "Risk and loses", but risk and lose is the integral part of any and every investment, the whole stock market is a "Casino game" like Operation, heavily manipulated. Therefore, there is no one sector that is good or bad, except "Precious Metals Sector" that no one can control for ever, it will always Crush the controllers?. Therefore, Penny stocks are a "Must" to include in any part of investment, do your own diligence and study penny stocks, you will be rewarded. PENNY STOCKS ARE A GREAT OPPORTUNITY SECTOR: BUT, YOU MUST DO YOUR OWN DUE DILIGENCE!!!!!!.
FYI: This boards posts and contents are "Not Advice or Recommendation", So, Everyone must do their own due diligence as far as investing or trading is concerned.
Note: No abuse of any kind such as bullying or bashing or P&Ds or any sort of fake claims will NOT BE permitted, comments will be moderated and inappropriate posts will be removed.
If you have interesting Penny stock or otc stock, bring it to the board for dicsussion or exposure, board wellcomes Posts, Comments and discussions, the board and pages here are for learning and understanding purpose, and are mostly just Views and Opinions. Also discussed are stock technicals, Charts and news related to Penny stocks activities.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |